MedTrace Logo

A Study to Evaluate the Safety, Tolerability and Efficacy of RZ-001 in Combination With Valganciclovir (VGCV) and Atezolizumab/Bevacizumab in Subjects With Hepatocellular Carcinoma

NCT06695026 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 45

Last updated 2025-07-29

No results posted yet for this study

Summary

This study is to evaluate the safety, tolerability, efficacy and immunogenicity of RZ-001 in combination with Valganciclovir (VGCV) and Atezolizumab/Bevacizumab when given to subjects with human telomerase reverse transcriptase (hTERT)-positive HCC.

Conditions

  • Hepatocellular Carcinoma (HCC)

Interventions

DRUG

RZ-001 Dose 1

RZ-001 Dose 1 and VGCV, Atezolizumab/Bevacizumab

DRUG

RZ-001 Dose 2

RZ-001 Dose 2 and VGCV, Atezolizumab/Bevacizumab

DRUG

RZ-001 Dose 3

RZ-001 Dose 3 and VGCV, Atezolizumab/Bevacizumab

Sponsors & Collaborators

  • Rznomics, Inc.

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-12-18
Primary Completion
2027-08-31
Completion
2027-10-31
FDA Drug
Yes

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06695026 on ClinicalTrials.gov